Hu Jian, Jia Qiuyu, Zhang Wenge, Zhang Jianzhong, Li Houmin
Department of Dermatology, Peking University People's Hospital, Beijing, People's Republic of China.
Clin Cosmet Investig Dermatol. 2024 Nov 28;17:2713-2723. doi: 10.2147/CCID.S487996. eCollection 2024.
Topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE-4) inhibitors are three common topical anti-inflammatory agents for treating atopic dermatitis (AD). The purpose of our study was to understand Chinese dermatologists' perceptions and the factors influencing their choices of the three agents.
An online questionnaire survey was conducted between 25 July 2022 and 25 August 2022 among Chinese dermatologists. The survey with six multiple-choice questions focused on what were their most commonly prescribed agents for treating AD, and what factors influenced their choices of the three agents. The results were assessed by chi-square test and logistic regression analysis.
A total of 1, 156 valid questionnaire replies were received. For treating AD, 79.84% of Chinese dermatologists chose TCS, 81.40% chose TCI, and 18.25% chose PDE-4 inhibitors. When TCS was not chosen, the three principal reasons included local adverse effects (85.56%), suspicious infection on lesioned area (71.54%), and patient steroid phobia (61.59%). Coincidentally, when the TCI and PDE-4 inhibitors were chosen, the main reason was patient steroid phobia (76.21% and 74.74% respectively) against TCS. When PDE-4 inhibitors were not chosen, the major reasons were their intolerable adverse effects (80.36%) and their slower onset and weak efficacy (57.61%). Logistic regression analysis revealed that more senior dermatologists were less likely to choose TCS for the reason of local adverse effects and patient steroid phobia (each < 0.05), they were more likely to choose TCI for the same reason of patient steroid phobia against TCS ( < 0.05).
Local adverse effects and patient steroid phobia were the reasons that limited Chinese dermatologists from choosing TCS for treating AD. Instead, more of them choose to use TCI. PDE-4 inhibitors were sometimes considered as an alternative to TCS or TCI, but its local adverse effects and limited efficacy affected the choice of this agent.
外用糖皮质激素(TCS)、外用钙调神经磷酸酶抑制剂(TCI)和磷酸二酯酶4(PDE - 4)抑制剂是治疗特应性皮炎(AD)的三种常见外用抗炎药。我们研究的目的是了解中国皮肤科医生对这三种药物的看法以及影响他们选择的因素。
于2022年7月25日至2022年8月25日对中国皮肤科医生进行了一项在线问卷调查。该调查有六个多项选择题,重点关注他们治疗AD最常用的药物是什么,以及哪些因素影响了他们对这三种药物的选择。结果通过卡方检验和逻辑回归分析进行评估。
共收到1156份有效问卷回复。对于治疗AD,79.84%的中国皮肤科医生选择TCS,81.40%选择TCI,18.25%选择PDE - 4抑制剂。当未选择TCS时,三个主要原因包括局部不良反应(85.56%)、皮损部位疑似感染(71.54%)和患者激素恐惧症(61.59%)。巧合的是,当选择TCI和PDE - 4抑制剂时,主要原因是患者对TCS的激素恐惧症(分别为76.21%和74.74%)。当未选择PDE - 4抑制剂时,主要原因是其难以耐受的不良反应(80.36%)以及起效较慢和疗效较弱(57.61%)。逻辑回归分析显示,更资深的皮肤科医生因局部不良反应和患者激素恐惧症而不太可能选择TCS(均<0.05),出于患者对TCS的激素恐惧症这一相同原因,他们更有可能选择TCI(<0.05)。
局部不良反应和患者激素恐惧症是限制中国皮肤科医生选择TCS治疗AD的原因。相反,他们更多地选择使用TCI。PDE - 4抑制剂有时被视为TCS或TCI的替代品,但其局部不良反应和有限的疗效影响了对该药物的选择。